ELVElevance Health
$439.89+28% 1Y
$439.89
$277.8952 weeks$445.34
The financials
Elevance Health by the numbers
Elevance Health (ELV) reported revenue of $51.4B in Q3 2026 (quarter ended Sep 30, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 89% and net income of $1.36B (2.7% of revenue). For the full year FY2025, revenue was $199.1B (+12% year on year) and net income $5.66B. Its largest segment in Q2 2026 (quarter ended Jun 30, 2026) was Reportable at $50.5B, 89% of the disclosed total, well ahead of Carelon Rx at 11%. The next results filing is expected around Jan 27, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $51.4B | $50.7B | +1.4% |
| Gross profit | $45.8B | $45.3B | +1.0% |
| Operating income | $1.27B | $1.29B | −2.0% |
| Net income | $1.36B | $1.19B | +15% |
| Diluted EPS | $6.27 | $5.32 | +18% |
| Operating | Revenue | Share |
|---|---|---|
| Reportable | $50.5B | 89% |
| Carelon Rx | $6.26B | 11% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $56.74B (+0.59%)
Carelon Rx grew +3.7% year on yearReportable +1.4% year on year
Segment Latestquarter on quarteryear on year
- Reportable$50.47B$50.47Bquarter on quarter +0.58%year on year +1.4%+0.58%+1.4%
- Carelon Rx$6.26B$6.26Bquarter on quarter +0.63%year on year +3.7%+0.63%+3.7%
- Carelon Services$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Corporate And Other$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Health Benefits$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
Healthcare
Ranks #18 of 436 by RyuScore